The minimum total value of these contracts is $650,000 and $210,000 respectively. These new orders bring the minimum total value of pharmaceutical clinical trial contracts secured by AtCor in the past eight months to over $6.5 million.
Duncan Ross, CEO of AtCor Medical, said: “We continue to execute on our strategy, which is producing strong growth despite a tough macroeconomic environment. These new contracts show the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical and biotechnology clinical trials, as well as SphygmoCor’s significance as a drug therapy management tool in clinical practice.”